ApplyBlast uses AI to match you with the right jobs, tailor your resume and cover letter, and apply automatically so you can land your dream job faster.
© All Rights Reserved. ApplyBlast.com
ApplyBlast uses AI to match you with the right jobs, tailor your resume and cover letter, and apply automatically so you can land your dream job faster.
© All Rights Reserved. ApplyBlast.com
The University of British Columbia
A Postdoctoral Research Fellow at the University of British Columbia works on developing a novel lipid nanoparticle-mRNA platform for functional gene delivery in cancer. The role involves nanoparticle preparation, transcriptomic analysis, and preclinical cancer model studies.
The University of British Columbia is a global centre for research and teaching, consistently ranked among the top 20 public universities in the world.
Business WireAlloy Therapeutics and University of British Columbia Partner to Accelerate Antibody Discovery with Cryo-Electron Microscopy Technology
Oct 7, 2025
CBCB.C.'s biggest ski resort offers discounts for people aged 13 to 30
3 days ago
Business ExaminerBRITISH COLUMBIA MOVERS & SHAKERS FEBRUARY 27, 2026
2 weeks ago
Headquarters
San Francisco, CA
Company Size
201-500 employees
Founded
2018
Industry
Technology
Glassdoor Rating
4.2 / 5
Sarah Johnson
Chief Executive Officer
Michael Chen
Chief Technology Officer
Emily Williams
VP of Engineering
David Rodriguez
VP of Product
Jessica Thompson
Chief Financial Officer
Andrew Park
VP of Sales
View leadership team, funding history,
and employee contacts for The University of British Columbia.
17% below the average for this role
Poets&Quants for UndergradsAlexandre Corhay Rotman School of Management University of Toronto
Dec 1, 2025
Scientist, Formulation Discovery
Eli Lilly and Company
Postdoctoral Research Associate - Therapeutic Genome Engineering
St. Jude Children's Research Hospital
Postdoctoral Fellow
mountsinaihospital.com
Lipid Nanoparticle & mRNA Synthesis Intern
Sartorius
Post Doctoral Scholar
The Ohio State University
Scientist II, LNP
CRISPR Therapeutics
